

Title	Yeast β -glucan improves insulin sensitivity and hepatic lipid metabolism in mice humanized with obese type 2 diabetic gut microbiota
Authors	Mitchelson, Kathleen A. J.;Tran, Tam T. T.;Dillon, Eugene T.;Vlckova, Klara;Harrison, Sabine M.;Ntemiri, Alexandra;Cunningham, Katie;Gibson, Irene;Finucane, Francis M.;O'Connor, Eibhlís M.;Roche, Helen M.;O'Toole, Paul W.
Publication date	2022-08-29
Original Citation	Mitchelson, K. A. J., Tran, T. T. T., Dillon, E. T., Vlckova, K., Harrison, S. M., Ntemiri, A., Cunningham, K., Gibson, I., Finucane, F. M., O'Connor, E. M., Roche, H. M. and O'Toole, P. W. (2022) 'Yeast β -glucan improves insulin sensitivity and hepatic lipid metabolism in mice humanized with obese type 2 diabetic gut microbiota', Molecular Nutrition and Food Research, 66(22), 2100819 (13pp). https://doi.org/10.1002/mnfr.202100819
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1002/mnfr.202100819
Rights	© 2022, John Wiley & Sons Ltd. This is the accepted version of the following item: Mitchelson, K. A. J., Tran, T. T. T., Dillon, E. T., Vlckova, K., Harrison, S. M., Ntemiri, A., Cunningham, K., Gibson, I., Finucane, F. M., O'Connor, E. M., Roche, H. M. and O'Toole, P. W. (2022) 'Yeast β -glucan improves insulin sensitivity and hepatic lipid metabolism in mice humanized with obese type 2 diabetic gut microbiota', Molecular Nutrition and Food Research, 2100819, doi: 10.1002/mnfr.202100819, which has been published in final form at: https://doi.org/10.1002/mnfr.202100819 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Download date	2026-10-30 02:37:29
Item downloaded from	https://hdl.handle.net/10468/13546



University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Yeast β -glucan improves insulin sensitivity and hepatic lipid metabolism in mice humanized with obese type 2 diabetic gut microbiota

Author Names and Affiliations

Kathleen A.J. Mitchelson^{1,14}, Tam T.T. Tran^{2,3,13,14}, Eugene T. Dillon⁴, Klara Vlckova^{2,3}, Sabine M. Harrison⁵, Alexandra Ntemiri^{2,3}, Katie Cunningham^{6,7}, Irene Gibson⁷, Francis M. Finucane^{6,8}, Eibhlís M. O'Connor^{2,9,10}, Helen M. Roche^{1,11,12,15} and Paul W. O'Toole^{2,3,15}

¹Nutrigenomics Research Group and Institute of Food and Health, University College Dublin, Dublin, Republic of Ireland

²APC Microbiome Ireland, University College Cork, Cork, Republic of Ireland

³School of Microbiology, University College Cork, Cork, Republic of Ireland

⁴Mass Spectrometry Resource, Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Republic of Ireland

⁵UCD School of Agriculture & Food Science, University College Dublin, Dublin, Republic of Ireland

⁶Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Republic of Ireland

⁷Croi, the West of Ireland Cardiac Foundation, Heart and Stroke Centre, Moyola Lane, Newcastle, Galway, Republic of Ireland

⁸HRB Clinical Research Facility, National University of Ireland, Galway, Republic of Ireland

⁹Department of Biological Sciences, School of Natural Sciences, University of Limerick, Limerick, Republic of Ireland

¹⁰Health Research Institute, University of Limerick, Limerick, Republic of Ireland

¹¹Diabetes Complications Research Centre, University College Dublin, Dublin, Republic of Ireland

¹²The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom

¹³Present address: University of Science and Technology of Hanoi, Vietnam Academy of Science and Technology, Hanoi, Vietnam

¹⁴These authors contributed equally

¹⁵Senior authors contributed equally

Lead Contact & Corresponding Author: Prof. Helen M. Roche, UCD Conway Institute and School of Public Health, Physiotherapy and Sports Science, University College Dublin, Belfield, Dublin 4, Republic of Ireland

Phone: 353-1-716-6845 Email: helen.roche@ucd.ie

Fax: 353-1-716-6701

Abbreviations: HFD, high-fat diet; HOMA-IR, insulin resistance index; MUFA, monounsaturated fatty acids; OBD, obese diabetic; OBH, obese healthy; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; TAG, triacylglycerol.

Keywords

Gut microbiota, hepatic triacylglycerol (TAG), high-fat diet, type 2 diabetes, yeast β -glucan.

Received: MONTH DD, YYY; Revised: MONTH DD, YYY; Accepted: MONTH DD, YYY

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/mnfr.202100819](#).

This article is protected by copyright. All rights reserved.

Abstract

Scope: Gut microbiota alterations are associated with obesity and type 2 diabetes. Yeast β -glucans are potential modulators of the innate immune-metabolic response, by impacting glucose, lipid and cholesterol homeostasis. We examined whether yeast β -glucan interacts differentially with either an obese healthy or obese diabetic gut microbiome, to impact metabolic health through hepatic effects under high-fat dietary challenge.

Methods and Results: Male C57BL/6J mice were pre-inoculated with gut microbiota from obese healthy (OBH) or obese type 2 diabetic (OBD) subjects, in conjunction with a high-fat diet (HFD) with/without yeast β -glucan. OBD microbiome colonization adversely impacted metabolic health compared to OBH microbiome engraftment. OBD mice were more insulin resistant and displayed hepatic lipotoxicity compared to weight matched OBH mice. Yeast β -glucan supplementation resolved this adverse metabolic phenotype, coincident with increasing the abundance of health-related bacterial taxa. Hepatic proteomics demonstrated that OBD microbiome transplantation increased HFD-induced hepatic mitochondrial dysfunction, disrupted oxidative phosphorylation, and reduced protein synthesis, which were partly reverted by yeast β -glucan supplementation.

Conclusions: Hepatic metabolism was adversely affected by OBD microbiome colonization with high-fat feeding, but partially resolved by yeast β -glucan. More targeted dietary interventions that encompass the interactions between diet, gut microbiota and host metabolism may have greater treatment efficacy.

Introduction

The prevalence of diabetes continues to rise worldwide [1]. Type 2 diabetes accounts for 90-95% of diagnosed diabetes cases which affected more than 500 million people worldwide in 2018, which is an underestimation since many cases are undiagnosed [2, 3]. Metformin is an effective therapeutic; however, there are opportunities for alternative diet-mediated therapeutic regimes which may interact with the gut microbiome. Effective dietary intervention is an increasingly important alternative to drug therapy and there is growing interest in how this may interact with the gut microbiome to improve metabolic health [4]. Modification of dietary fatty acid composition improves several components of metabolic-inflammation that typify insulin resistance and type 2 diabetes. Saturated fatty acids (SFA) drive insulin resistance, metabolic dysfunction and inflammation [5, 6]. Reducing dietary SFA attenuates insulin resistance in humans, improving both hepatic steatosis and adipose inflammation in animal models [7-10]. Dietary fiber also reduces

insulin resistance and type 2 diabetes incidence, depending on fiber type [11]. The gut microbiome is a potential modifier of diabetes risk [12], which in turn is modified by dietary composition [13]. Numerous studies suggest that metformin alleviates type 2 diabetes partly by reconfiguring gut microbiota composition [14]. It is reported that the human gut microbiota interacts with host metabolism to augment obesity, insulin resistance and type 2 diabetes through several effectors, including lipopolysaccharide, short-chain fatty acids, bile acids and branched chain amino acids [12, 14, 15].

β -glucans, particularly β -(1 $\rightarrow$ 3)-glucan, are naturally occurring fibers with diverse functionality, dependent upon their source and structural features [16], wherein some may improve insulin, glucose, lipid and cholesterol metabolism [17-19]. Additionally, yeast β -glucan has quite unique purported effects with respect to innate immune training. A supra-physiological intervention demonstrated that such β -glucan derived from *Akkermansia* spp. improved glycaemic control, hepatic steatosis and adipose inflammation in high-fat diet (HFD) induced obese / type 2 diabetes mouse model [20]. However, that dose also attenuated weight gain, which may have influenced metabolic changes. Feeding an alternative barley β -glucan lowered plasma cholesterol and elevated abundance of *Bifidobacterium* spp. and *Akkermansia muciphila* in patients with the metabolic syndrome, suggesting that the gut microbiota may modulate the diet-induced metabolic response [21]. However, the potential interactions between yeast β -glucan supplementation and the obese and/or diabetic subject's gut microbiome, in a weight-neutral context, are not fully understood.

To address this question, we colonized antibiotic-treated C57BL/6J mice with human microbiota from either obese healthy (OBH) or obese type 2 diabetic (OBD) subjects not receiving metformin. The murine recipients of the OBD human microbiome displayed insulin resistance, hepatic triacylglycerol (TAG) and cholesterol accumulation, with significant re-configuration of the hepatic proteome, particularly with respect to protein synthesis and fatty acid metabolism pathway signatures. Gut microbiota composition and diversity responded positively to the consumption of β -glucans accompanied by partial recovery of the OBH microbiome, amelioration of HFD-induced insulin resistance, and normalization of hepatic TAG and cholesterol levels in this humanized murine model.

Materials and Methods

Participant Recruitment and Faecal Sample Collection

Obese (BMI > 30 kgm⁻²) subjects were recruited from the Croí Heart and Stroke Centre, Galway, Ireland and written informed consent obtained. Ethical approval was granted from the Clinical Research Ethics Committee at Galway University Hospitals (C.A. 1782) and adheres to the Declaration of Helsinki and Research Ethics Committee, Ireland guidelines. Fasting blood samples were obtained for metabolic biomarkers. Two groups, obese healthy and obese diabetic, were recruited based on their glucose tolerance. Glucose tolerance status was determined using HbA1c and fasting glucose; with obese healthy (OBH) indicated by fasting glucose levels of <6 mmol/L and HbA1c of <42 mmol/mol and obese diabetic (OBD) defined by a fasting glucose >7 mmol/L and HbA1c of $\geq$ 48 mmol/mol. A freshly voided (same day) faecal sample was collected and maintained in an anaerobic environment from time of collection until same-day processing and preparation for mice humanization.

Faecal Microbiota Transplantation

Faecal microbiota transplantation from humans to mice was performed as described previously by our lab [22]. In brief, faecal samples from the selected donors were collected immediately upon voiding and transferred to a plastic container from which oxygen was expunged by commercial anaerobic culture envelopes. The samples were moved immediately to the lab, opened in an anaerobic hood, diluted 1:10 mass/volume in pre-reduced PBS containing 20% glycerol, and mixed gently till an even suspension was formed. Aliquots of 1 mL were flash-frozen on dry ice, then stored at -80°C till required.

Mice and Study Design

Male C57BL/6J mice were obtained from Envigo, United Kingdom. A schematic overview of the experimental study design is presented in **Figure 1A**. At 5 weeks of age, mice received an antibiotic cocktail of ampicillin (1 g/L), metronidazole (1 g/L), vancomycin (500 mg/L), imipenem (250 mg/L) and ciprofloxacin HCl (200 mg/L) for 6 weeks in their drinking water to deplete the murine gut microbiota [22, 23]. An anti-fungal (Amphotericin B, 0.1 mg/mL) was given by oral gavage (1 daily on the first and last 3 days of antibiotic treatment). Following antibiotic treatment, after one day of wash out, mice were inoculated with human microbiota derived from either an obese healthy or an obese diabetic subject. Faecal material (300 µL of a prepared slurry) was orally administered in two 50 µL doses per day for 3 consecutive days. From 9 weeks old, mice were fed a low-fat diet (LFD; 10% kcal from fat). After 2 weeks, half of the cohort was changed to a LFD with β -glucan for 4 weeks, before being fed the high-fat diet (HFD; 45% kcal from fat) with and without β -glucan for 9 weeks. The primary objective was to determine the interaction between different microbiota and yeast β -glucan supplementation on metabolic health. To this end, faecal microbiome transfer (FMT) was completed and initially mice were fed a LFD with/without yeast β -glucan to acclimatize the animals. However, within any human OBH or OBD phenotype, it is most probable that a habitual high-fat diet is consumed, therefore all animals were challenged with a high-fat diet (HFD) with/without β -glucan. The β -glucan dose was equivalent to 50 mg/kg/day. Whilst the recommended daily dose of Wellmune in human is 2.5 mg/kg, we fed a higher dose (50 mg/kg) to investigate the microbiome interaction concept, over a short-time frame as compared to long-term human habitual consumption. Additionally, this dose is in line with previous animal studies yeast β -glucan ingestion on microbiome and hepatic health [20]. All diets were purchased from Research Diets (New Brunswick, NJ, USA) with β -glucan (Wellmune®) supplied by Kerry. Mice were housed in metabolic cages in a 12:12-h light-dark cycle and fed *ad libitum*. Body weight and food intake were measured weekly. Faecal samples were collected at several time points. Mice were anaesthetised (5% isoflurane gas inhalation), euthanised by cervical dislocation and tissues were then isolated for analysis. All experiments were approved by the Animal Ethics Experimentation Committee of University College Cork (AE19130/P072).

Microbiota profiling and metagenomics

Total genomic DNA extracted from human faecal and murine faecal samples was used as a template in library preparation for 16S rRNA gene amplicon sequencing of the V3-V4 variable region [24]. Purified amplicons were pooled in equal volumes. Sequencing (2 x 250 bp) of the pooled library was performed using Illumina MiSeq (Illumina, Inc., San Diego, CA, USA) in the Eurofins GATC Biotech GmbH (Constance, Germany). We applied a similar bioinformatic analysis of 16S amplicon sequencing data as previously published [22]. Details of methods are presented in **Supplementary Text**.

Metagenomic libraries of human faecal samples were prepared using the Nextera XT DNA Library Prep Kit (Illumina) and sequenced using Illumina NextSeq® 500/550 High Output v2 (300 cycles) at the National Irish Sequencing Centre (Teagasc Food Research Centre, Ireland) to generate 150 bp paired-end read libraries.

Glucose and Insulin Tolerance Tests

Mice were fasted overnight for 12h then injected intraperitoneally with 25% (wt/vol) glucose (1.5 g/kg; B. Braun Medical, Dublin, Ireland) for glucose tolerance testing (GTT). Mice were fasted for 6 hours then injected intraperitoneally with insulin (0.5 U/kg; Actrapid, Novo Nordisk, Denmark) for insulin tolerance test (ITT). Glucose levels were measured at baseline, 15, 60, 90, and 120 minutes post glucose/insulin challenge by an accu-check glucometer (Roche, Dublin, Ireland). Tail-vein bleeds were sampled at baseline as well as 15 and 60 minutes post glucose challenge to measure the insulin secretory response. ELISA (Crystal Chem, Inc., IL, USA) was used to quantify insulin levels post glucose challenge.

Hepatic Triacylglycerol, Cholesterol, Citrate and Lactate Quantification

Flash frozen liver tissue (50 mg) was homogenized in a TissueLyser II (Qiagen Cat. No. / ID: 85300). For triacylglycerol and cholesterol assays, liver homogenate was prepared as previously described [25]. The dried sample was re-suspended in water before TAG and cholesterol analysis. Hepatic TAG (Wako LabAssay™ Triglyceride kit, Fuggerstraße, Neuss, Germany) and hepatic cholesterol (Wako LabAssay™ Cholesterol kit) was measured as per manufacturer's instructions. Hepatic citrate (Sigma-Aldrich Citrate Assay Kit) and lactate (Sigma-Aldrich Lactate Assay Kit) was measured as per manufacturer's instructions.

Gene Expression Analyses

RNA was extracted from 50 mg flash frozen hepatic tissue with Trizol. Chloroform was added, mixed by inversion and the colourless aqueous phase was transferred to a fresh tube. Isopropanol was added to precipitate the RNA overnight. RNA was quantified using a NanoDrop 8000 UV-Vis spectrophotometer. Equal amounts of cDNA were synthesized using the Applied Biosystems High Capacity cDNA kit (Applied Biosystems by Thermo Fisher Scientific). *Fasn*, *Cpt1α*, *Dgat1*, *Hmgcr*, *Abcg5*, *Abcg8*, *Gpr109a* primers and TaqMan Universal Mastermix were obtained from Applied Biosystems by ThermoFisher Scientific. mRNA expression was measured by real-time PCR on Applied Biosystems™ QuantStudio™ 7 Flex Real-Time PCR System. Housekeeping gene 18S was used for

hepatic gene expression. Comparison of 2-($\Delta\Delta Ct$) determined fold change as previously described [26].

Fatty Acid Analysis

Fatty acid methyl esters (FAMES) were prepared using the MARS 6 express 40 position microwave reaction system and quantified by gas chromatography (GC) as described previously [27]. Briefly, fatty acids were extracted from 50 mg flash frozen hepatic tissue using a microwave-assisted preparation of fatty acid methyl esters for GC analysis. Potassium hydroxide (10 mL, 2.5 % w/v) in methanol and internal standard (tricosanoic acid, 100 μ L, 10 mg/mL in chloroform) were added for saponification, microwaved and heated to 130°C, and held for 4 min. Methanolic acetyl chloride (15 mL, 5 % v/v) was added for esterification, microwaved, heated to 120°C in 4 min and held for 2 min. Pentane (10 mL) was added for fatty acid extraction and saturated sodium chloride (20 mL) was added to induce phase separation. Fatty acid methyl esters were measured using an Agilent 7890B gas chromatograph fitted with a flame ionisation detector (FID). Analytes were separated using a CP-Sil 88 capillary with a 100 m $\times$ 0.25 mm internal diameter $\times$ 0.2 μ m film thickness column. Compounds were identified by comparing their retention times with FAME Supelco standards. Peak area analysis was conducted using Agilent OpenLAB CDS 2.1 Workstation. The content of each fatty acid (mg/g of tissue) was calculated according to the following equation:

$$(\text{Peak Area (FAME)} / \text{peak area (ISTD)}) \times (\text{Weight ISTD} / \text{weight sample}) \times (\text{ISTD purity}) \times 10 = \text{content}$$

Hepatic Proteomic Analysis

Hepatic proteomic samples were prepared as described in **Supplementary Text**. Briefly, liver protein was isolated from 50 mg tissue with trichloroacetic acid (20%) and protein pellets were twice washed in ice-cold acetone before resuspension in 8M Urea in triethylammonium bicarbonate. Protein samples were in-solution digested in trypsin overnight at 37°C. After drying in vacuum centrifuge, peptides were acidified by acetic acid (AA), desalted with c18 STAGE tips [28], and resuspended in 2.5% acetonitrile (ACN), 0.5% AA. Peptide fractions were analyzed on a quadrupole Orbitrap (Q-Exactive, Thermo Scientific) mass spectrometer equipped with a reversed-phase NanoLC UltiMate 3000 HPLC system (Thermo Scientific). Raw data was processed using MaxQuant version 1.6.3.4 [29], incorporating the Andromeda search engine [30]. To identify peptides and proteins, MS/MS spectra were matched to the Uniprot mouse database. For the generation of label free quantitative (LFQ) ion intensities for protein profiles, signals of corresponding peptides in different nano-HPLC MS/MS runs were matched by MaxQuant in a maximum time window of 1 minute [31]. The Perseus computational platform (version 1.6.2.3) was used to process MaxQuant results [32]. Data were log transformed. *T*-test comparisons were carried out between liver proteomes. For visualization of data using heat maps, missing values were imputed with values from a normal distribution and the dataset was normalized by z-score.

Bioinformatic Pathway Analysis

Bioinformatic analysis was performed to analyze differentially expressed hepatic proteins. Briefly, *t*-test differences from proteomic analysis were uploaded into Qiagen's Ingenuity Pathway Analysis (IPA) system for core analysis and overlaid with the Ingenuity pathway knowledge base. IPA was performed to identify canonical pathways, and putative upstream regulators that are the most significant in global molecular networks [33]. These results were ranked based on their *p* value ($p \leq 0.05$) or activation score (*z*-score) of pathway activated/inhibition.

Statistical analysis

Statistical analysis was carried out using R v.3.5.5 software packages [34]. Significant differences in microbiome β diversity were detected using permutational multivariate analysis of variance (PERMANOVA) (vegan R package [35]). Differences of α diversity and different taxonomic levels were identified by Mann-Whitney U test for the comparison of two diet groups stratified by β -glucan consumption (unpaired data) and Wilcoxon signed rank test for the comparison between time points (paired data). *P*-values were adjusted for multiple comparisons using Benjamini–Hochberg correction.

Metabolic phenotype data were expressed as mean $\pm$ standard error of the mean (S.E.M). For GTT, ITT and insulin secretion a two-way repeated measures Analysis of Variance (ANOVA) was completed followed by a post hoc Bonferroni test (if the ANOVA reached statistical significance). For between-group comparisons, a one-way ANOVA followed by post-hoc Bonferroni test was performed. Analyses were completed using GraphPad Prism 5.0 software (GraphPad Prism Software, Inc, La Jolla, CA, USA)

Results

Microbiome differences in human subjects with obesity, with or without type 2 diabetes

The clinical characteristics and metformin treatment status of the OBD (obese type 2 diabetes) versus OBH (obese healthy (non-diabetic)) subjects demonstrated no significant difference with respect to age, BMI, or sex, but displayed elevated fasting glucose and HbA1c, as expected (**Table S1, Table S2**). There was no significant separation by β -diversity analysis of overall gut microbiota composition between obese healthy individuals and obese type 2 diabetes subjects, with or without metformin treatment (unweighted and weighted UniFrac measures: $p > 0.05$; **Figure S1A**). Although 16S rRNA amplicon sequencing was apparently biased towards higher proportions of *Lachnospiraceae*, compared with shotgun metagenomic sequencing, the proportional taxonomic composition between subjects was largely consistent by both amplicon sequencing and metagenomics (**Figure S1B**). Obese type 2 diabetic subjects treated with metformin displayed significant loss of the *Clostridiales* order (unclassified *Lachnospiraceae* genus and *Eubacterium eligens*) and higher abundance of *Streptococcus* spp. and *Lactobacillus* spp. compared to obese healthy subjects and altered microbial metabolic pathway abundances (**Figure S2A**). The increase in the relative abundance of *Lactobacillus* with metformin is established [36], as well as other re-configurations of the human gut microbiota. Therefore, we selected a non-metformin treated OBD subject and a representative OBH subject as donors for the human-to-mouse microbiome transplantation. The faecal microbial community from the OBH donor was close to other OBH subjects but was distant from the OBD donor (**Figure S1A**). *Ruminococcaceae* was present in higher

abundance in OBH donor compared to OBD donor. The two donors exhibited differences in relative abundance at bacterial species level (**Figure S2B**).

OBD microbiome transplantation induced insulin resistance and disrupted hepatic TAG and cholesterol metabolism, which was resolved by β -glucan supplementation

We humanized mice with the gut microbiome from the selected OBH or OBD human subjects (**Figure 1A**). OBD microbiome transplanted mice were more insulin resistant, glucose intolerant and hyperinsulinemic following high-fat diet (HFD), compared to OBH inoculated mice. Interestingly, yeast β -glucan supplementation partly corrected the adverse OBD/HFD-induced metabolic phenotype, wherein fasting insulin concentrations and HOMA-IR, were significantly lower in the OBD+ β -glucan group, compared to the OBD/HFD microbiome-induced group (**Figure 1B-E**). Total weight gain, adipose depot weights and energy intake were not different between groups (data not shown).

Hepatic TAG and cholesterol levels were significantly higher in OBD mice compared to OBH mice (**Figure 1F-G**). Metabolite measurement revealed that hepatic citrate (**Figure 1H**) and lactate (**Figure 1I**) levels increased in OBD mice, but not when supplemented with β -glucan. Markers of lipid and cholesterol homeostasis were determined. Hepatic fatty acid synthesis (*Fasn*) was not significantly different. Hepatic *Cpt1 α* mRNA, an indicator of mitochondrial fatty acid oxidation, was increased in OBD mice which was further enhanced by β -glucan supplementation, compared to OBH. In terms of cholesterol regulation, expression of the cholesterol transporter *Abcg8* was lower in OBD mice (**Figure 1J**). Hepatic fatty acid composition was not significantly affected by microbiome source (**Table S3**).

The OBD microbiota composition moves towards a health-associated composition upon yeast β -glucan supplementation

Mouse faecal microbiome profiling by 16S rRNA gene amplicon sequencing was completed at key timepoints post-transplantation (**Figure 1A**). Sequences assigned to ten bacterial genera that were detected in the microbiome of at least 50% of the mice in the antibiotic pre-treatment group were not found in the humanized mice, indicating their successful eradication. Meanwhile, of 17 genera of the human microbiome present in less than 50% in the pre-treatment mouse group, only four genera including *Faecalibacterium*, *Bilophila*, *Dialister*, and *Megamonas* were not engrafted in the antibiotic-treated mice. Twenty-eight genera were detected in both the human donor and pre-treatment mouse stools, only five of which (*Desulfovibrio*, *Clostridium* XIVb, *Parasutterella*, *Bifidobacterium*, and *Gemmiger*) were absent in the humanized mice (**Figure S3**). Overall, the engraftment of human microbiota into antibiotic-treated mice appeared successful with a significant change in the murine gut microbiota before and after antibiotic treatment and transfer.

The α -diversity (diversity within samples) measured by Phylogenetic Diversity and Observed Species was consistently lower at week 1, and remained stable or increased slightly from week 3 to week 12 in both OBH and OBD (**Figure S4A**). The net increase in diversity during subsequent weeks was expected because the murine gut microbiota diversity had been lowered sharply by the administration of antibiotics and the engraftment of the human gut microbiota into antibiotic-treated mice allowed some sub-dominant taxa increase to more measurable proportions. In line with differences in the donor's gut microbiota, the α -diversity in the recipient mice in the OBD group was lower than that of OBH, but both exhibited lower microbial diversity than their respective

donors (**Figure S4B**). Yeast β -glucan supplementation increased α -diversity of the gut microbiota in OBD mice at week 3 (phylogenetic diversity: $p=0.006$, observed species: $p=0.01$), but no statistically significant differences in diversity were associated with β -glucan consumption from week 5 to week 12, when mice were receiving the HFD. However, the OBH+ β -glucan group showed lower phylogenetic diversity, compared to those without β -glucan supplementation at week 3 ($p=0.001$, **Figure 2A**). This result indicates that β -glucan supplementation while on a LFD, prior to the HFD, temporarily lowered microbiota diversity in a normal microbiota, but increased bacterial diversity in low-diversity communities.

We next investigated the relatedness of the microbiota community structures (β -diversity) between OBH and OBD, with or without β -glucan supplementation (**Figure 2B**). Principal coordinates analysis (PCoA) based on a Bray-Curtis dissimilarity (which measures microbiota dissimilarity) at week 1 showed the main separation was between the human donor metabolic phenotype (PERMANOVA: $R^2=0.31$, $p=0.001$). Supplementation with β -glucan at this early time-point had a marginal effect in OBD (PERMANOVA: $R^2=0.18$, $p=0.047$), but no impact on OBH (PERMANOVA: $R^2=0.05$, $p=0.529$). By week 3, the β -glucan effect on the microbiota was significant for both donor types, but more strikingly, β -glucan supplementation moved the OBD microbiota closer to that of the OBH group (**Figure 2B**). This effect was retained at week 5, but the β -glucan supplementation effect on the microbiota was weaker within metabolic phenotypes (OBH versus OBD). By week 10 when mice had received a longer period of HFD diet, there was general convergence, although β -glucan supplementation still had a significant effect within the OBD microbiota (PERMANOVA: $R^2=0.18$, $p=0.027$). Yeast β -glucan supplementation had a greater effect on OBD microbiota during the LFD phase than HFD phase. When all time points were mapped, the murine microbiota datasets were more similar to the respective human donor microbiota than the pre-treatment mouse microbiota at week 6 (**Figure S5A**). β -glucan supplementation significantly separated mice in the PCoA, but distances were reduced upon HFD over time especially in the OBD group. Furthermore, changes in gut microbiota (measured with Bray-Curtis dissimilarity) throughout HFD versus LFD diet periods accompanied by β -glucan consumption particularly in week 10 were significantly lower than in mice not supplemented with β -glucan. This suggests that β -glucan might reduce the effect of HFD on gut microbiota in both OBD and OBH (**Figure S5B**).

β -glucan responsive taxa differ between OBD and OBH inoculated mice

Analysis of differentially abundant taxa showed increased relative abundance of *Verrucomicrobiaceae*, *Ruminococcaceae*, *Desulfovibrionaceae*, *Porphyromonadaceae* and a decrease in *Streptococcaceae*, *Bacteroidaceae*, *Rhodospirillaceae*, *Enterobacteriaceae* with β -glucan supplementation. *Flavonifractor*, *Akkermansia*, *Roseburia*, *Parabacteroides* in the OBH group and *Clostridium XIVa*, *Odoribacter*, *Anaerostipes* in the OBD group were significantly higher after β -glucan supplementation. *Escherichia/Shigella* abundance was consistently lower at all time points in the OBH+ β -glucan group (**Supplementary Text, Figure S6**).

At the species level, 69 known species accounted for $73.2\pm 19\%$ (mean $\pm$ SD) of the microbial composition abundance across all samples. Most samples were dominated by *Akkermansia muciniphila*, and *Bacteroides vulgatus*, although the OBH group was also dominated by *Parabacteroides distasonis* and *Bacteroides xylanisolvens*. *Bacteroides uniformis* was dominant in the OBD group, particularly when not supplemented with β -glucan (**Figure 3A**). *Akkermansia muciniphila* was initially more abundant with β -glucan supplementation, but this was not maintained in OBD

mice on HFD. *Bacteroides vulgatus*, *Alistipes massiliensis*, *Blautia hydrogenotrophica*, *Odoribacter splanchnicus* were significantly more abundant in at least two consecutive time points in OBD+ β -glucan mice. The opposite applied for *Clostridium paraputrificum*, *Clostridium ramosum*, *Bacteroides uniformis*. In contrast, higher abundance of *Parabacteroides distasonis*, *Akkermansia muciniphila* and lower abundance of *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, *Bacteroides acidifaciens* were associated with β -glucan supplementation in the OBH group prior to and throughout the HFD (**Figure 3B** and **Figure 3C**). This suggests the effect of β -glucan on certain specific taxa was more stable in OBH than in OBD, even after HFD.

We found moderate correlations between the abundance of several gut microbial OTUs and the host expression of *Cpt1 α* , *Abcg8* genes and HOMA-IR (Spearman's correlation analysis: $|\rho| < 0.62$, nominal p -values < 0.05) but these associations lost significance after adjustment for multiple testing except the association of OTU_1183 (unclassified *Clostridium* XIVa) and *Cpt1 α* (**Figure S7**). In particular, OTU_1290 (*Alistipes massiliensis*) and OTU_501 (*Bacteroides vulgatus*) belonging to the species that differed significantly in abundance upon yeast β -glucan supplementation were negatively correlated with HOMA-IR. Similarly, negative correlations were observed between *Abcg8* expression gene and the abundances of OTU_456 (*Flavonifractor plautii*), OTU_75 (*Oscillibacter valericigenes*), OTU_612 (*Parabacteroides distasonis*). The hepatic *Cpt1 α* mRNA level was positively correlated with OTU_265 (*Bacteroides uniformis*) but inversely with OTU_239 (*Bacteroides thetaiotaomicron*). Collectively, these findings suggest the impact of gut microbiota upon hepatic gene expression as well as the insulin resistance score HOMA-IR, by currently unknown mechanisms.

Hepatic proteomic expression is altered by both microbiome type and β -glucan supplementation

The liver is a central organ that integrates signals from the gut, pivotal for regulating metabolism. To identify mechanisms underpinning diet/microbiome induced changes in metabolism, hepatic mass spectrometry (MS)-based proteomics was performed, comparing the OBD mice, the most adverse metabolic phenotype, with OBH as the control or relative comparator. A total of 102 proteins were differentially expressed between OBD and OBH livers, 25 increased in abundance and 77 proteins were decreased (**Figure 4A**). In conjunction with the improved phenotype, 66 differentially expressed proteins (20 increased and 46 reduced) involved in fatty acid metabolism, mitochondrial dysfunction and inflammation between OBD and OBD+ β -glucan livers (**Figure 4B**). Hepatic proteomic comparison between OBH+ β -glucan versus OBH displayed 132 increased and 161 decreased proteins totaling 293 differentially expressed proteins (data not shown). However, the hepatic metabolic phenotype was not significantly different in OBH mice fed β -glucan compared to those who were not.

Ingenuity pathway analysis (IPA) identified key pathways that were differentially expressed between OBD and OBH (**Figure 4C**), and between OBD mice fed β -glucan and OBD hepatic proteomes (**Figure 4D**). Interestingly, the pathways most modulated by OBD versus OBH microbiome colonization differed by magnitude of alteration, compared to those associated with β -glucan supplementation in OBD mice, wherein hepatic steatosis and insulin resistance was partly resolved. Specifically, mitochondrial dysfunction, EIF2 signaling, oxidative phosphorylation, the sirtuin signaling pathway and regulation of EIF4 and p70S6K signaling were significantly affected in the OBD group (**Table S4**). The most significant pathways in OBD+ β -glucan included EIF2 signaling, regulation of EIF4 and p70S6K signaling, mTOR signaling, mitochondrial dysfunction and tRNA charging (**Table S6**).

The top canonical pathways that were differentially up- or down-regulated in OBD versus OBH livers are listed in **Table S4**. Key pathways inhibited in OBD livers include tRNA charging, EIF2 signaling, citrulline metabolism, citrulline biosynthesis and unfolded protein response. In contrast, galactose degradation, RhoGDI signaling, SPINK1 Pancreatic Cancer Pathway, NRF2-mediated oxidative stress response and gluconeogenesis were up-regulated in OBD livers (**Table S4**). IPA also identified putative upstream regulators of changes in the proteomic dataset. MYCN, MYC, Glucagon, ACOX1 and CLPP were potential upstream regulators that were down-regulated in OBD mice (**Table S5**). Upstream regulators upregulated in OBD were PPARG, PNPLA2, ACS2, PCGEM1, FOXA2 and PPARG (**Table S5**). Importantly, several proteins, predominantly transcription factors, CEBPA, CEBPB, SREBF1, FOXO1, RXRA and SIRT1, were shared between key pathways. This indicates important coincident dysregulated regulation of hepatic mitochondrial, fatty acid, insulin, and glucose metabolism following diabetic microbiome inoculation and high-fat feeding in OBD liver.

Fewer canonical pathways were enriched or unenriched, when comparing OBD to OBD+ β -glucan (**Table S6**). The pathways include EIF2 signaling, tRNA charging and sirtuin signaling pathway, suggesting oxidative phosphorylation and fatty acid metabolism were altered by β -glucan. Putative upstream regulators inhibited within these pathways were RICTOR, INS1, BDNF and activated were MYC, MYN, SYVN1, XBP1 and NFE2I2 (**Table S7**). Of note, we found that the MYC family was inhibited in OBD livers but activated in OBD+ β -glucan. This could be a mechanism by which yeast β -glucan increased insulin sensitivity and reduced hepatic steatosis.

Discussion

The adverse metabolic impact of high-fat feeding was greatly accentuated after obese diabetic microbiome transplantation, compared to obese but metabolically healthy microbiome transplantation, in a humanized mouse model. Interestingly this adverse phenotype was partly rescued by yeast β -glucan supplementation. The adverse OBD microbiome induced metabolic phenotype was characterized by hyperinsulinemia, glucose intolerance and increased hepatic TAG and cholesterol levels, despite being weight matched. Interestingly, β -glucan supplementation reverted the OBD-induced hyperinsulinemia and HOMA-IR, despite high-fat feeding. Yeast derived β -glucan is a relatively novel functional food which is purported to enhance metabolism and innate immune training, as previously reviewed [16]. Dietary β -glucan functionality is highly dependent upon structure and source. The metabolic effects of a yeast β -glucan are less well defined compared to the well characterized impact of oat derived β -glucan which improves plasma lipid metabolism and circulating insulin levels [37, 38]. In humans, daily consumption of yeast β -(1,3/1,6)-D-glucan (15g/d for 8 weeks) lowered total cholesterol concentrations [39]. Another group has demonstrated that feeding very high doses of yeast β -glucan improved metabolic health, but that dose also resulted in increased faecal fat excretion that significantly impeded weight gain, which presumably confounded metabolic readouts [40]. Our findings are noteworthy because metabolic reconfigurations were in the obese state and dependent upon human microbiome source, without any weight change.

The liver is a first pass organ after the gut. Our data suggest synergy between the OBD microbiome and HFD, to induce greater hepatic TAG and cholesterol levels, despite equal weight gain as OBH microbiome recipients. Interestingly hepatic citrate and lactate levels increased in OBD-HFD mice. This suggests that the TCA cycle was disrupted, wherein citrate could be shuttled off into

Acyl CoA promoting *de novo* lipogenesis (DNL), which in conjunction with hyperinsulinemia might explain elevated hepatic TAG levels. In addition, HFD increased hepatic cholesterol levels in OBD microbiome recipients. Interestingly, cholesterol transporter *Abcg8* expression, which promotes hepatic cholesterol excretion, was reduced which may account for increased cholesterol levels [41].

This study was conducted using a limited number of individuals as faecal donors, because of the ethical, logistical and financial limits that necessarily pertain when transferring human microbiomes into animal models. Despite this restriction, our data confirm the evidence for a link between the gut microbiome and both type 2 diabetes and metformin treatment, suggesting that gut microbiota modulation could be a key target in type 2 diabetes management. Faecal microbiota transplant from humans to mice showed that several bacterial species were significantly differentially abundant between OBD or OBH microbiome inoculated mice. *Akkermansia muciniphila*, a well characterized mucin-degrading bacterium associated with metabolic health [42] rather than type 2 diabetes [43, 44], was significantly increased following β -glucan supplementation [20, 21]. In humans, direct *Akkermansia muciniphila* supplementation for three months improved insulin sensitivity and reduced total cholesterol levels in overweight/obese subjects [45]. OBH mice displayed a proportional reduction in total *Bacteroides* species. Specifically, *Bacteroides vulgatus* abundance has been associated with branched-chain amino acids biosynthesis and insulin resistance [12]. Here we observed that OBD β -glucan supplemented mice had increased abundance of *Bacteroides vulgatus*, *Alistipes massiliensis*, *Blautia hydrogenotrophica*, *Odoribacter splanchnicus* and decreased abundance of *Clostridium paraputrificum*, *Clostridium ramosum*, *Bacteroides uniformis*. In terms of speculating whether these taxa explain the improved metabolic phenotype of OBD+ β -glucan mice, *Clostridium ramosum* is associated with diet-induced obesity and type 2 diabetes [46]. *Odoribacter splanchnicus* is a well-characterized butyrate-producing bacterium [47] and *Blautia hydrogenotrophica*, which can produce acetate [48], may also contribute to modulating metabolism via short-chain fatty acid metabolites. In terms of relating the microbiome to key phenotypes in our study, some gut microbial OTUs from *Lachnospiraceae* sp., *Alistipes massiliensis*, *Bacteroides vulgatus* associated with yeast β -glucan supplementation, were negatively correlated with HOMA-IR, although these associations did not pass multiple testing correction. These bacteria can produce beneficial short-chain fatty acids which may regulate hepatic gluconeogenesis via the TCA cycle, to subsequent lower levels of HOMA-IR [49]. Whilst the abundance of different bacterial OTUs were also correlated with hepatic *Cpt1 α* , *Abcg8* gene expression, a potential functional relationship is, as yet, unknown. Indeed, these hepatic genes are affected by hepatic lipid, cholesterol and insulin concentrations [50, 51], therefore direct modulation via the microbiome is not necessarily the case. Future work is required to further validate if/how OBD microbiota and related metabolites, have functional effects in response to β -glucan supplementation.

Hepatic proteomic signatures were determined to elucidate mechanisms underpinning the impact of different microbiota and β -glucan supplementation on metabolic health. Several hepatic pathways were differentially regulated between OBD and OBH recipients in response to high-fat feeding. Those inhibited include the tRNA charging pathway which is responsible for attaching amino acids to tRNA to during protein synthesis. The EIF2 signaling pathway regulates mRNA translation, both specifically and globally, within the cell. The unfolded protein response (UPR) pathway is activated in response to endoplasmic reticulum (ER) stress resulting from unfolded or misfolding proteins. This suggests protein synthesis was inhibited in OBD livers. While we did not investigate

plasma amino acid profiles, it is well established that dysregulated amino acid metabolism plays a key role in type 2 diabetes [52, 53]. The citrulline metabolism and biosynthesis pathways were also inhibited in OBD livers. Citrulline is downstream of Acyl-CoA and glutamate in the urea cycle in hepatic mitochondria. This indicates inhibition of the urea cycle in OBD livers. Pathways which were activated in the OBD versus OBH groups include the galactose degradation pathway which is responsible for the degradation of D-galactose to enter the glycolysis pathway. Gluconeogenesis was also activated, which generates glucose from non-carbohydrate precursors. Signaling of RhoGDI, a chaperone which prevents Rho protein degradation and alters cellular growth and regeneration patterns was activated. NRF2-mediates oxidative stress response which is a regulator of cellular resistance to oxidants within the liver. This indicates higher glucose formation and utilization in conjunction with altered cellular growth patterns and increased oxidative stress within the OBD liver.

Pathway analysis also indicated putative upstream regulators that changed in OBD recipients in comparison to OBH recipients. MYC downregulation indicates inhibition of protein synthesis. Additional downregulated targets suggest increased glycolysis (glucagon), fatty acid accumulation (ACOX1) and alterations in mitochondria protein biogenesis, trafficking and degradation (CLPP). Activated upstream regulators in OBD hepatic tissue display altered gene transcriptions patterns specific to both fatty acid β -oxidation (PPARA, PNPLA2) and fatty acid storage (ACSS2). Thus, fatty acid metabolism/storage was greatly altered in OBD livers, as evidenced by higher TAG and cholesterol levels.

Even though β -glucan supplementation had important phenotypic effects with lower HOMA-IR and hepatic TAG accumulation, relatively few canonical pathways were predicted to be enriched or depleted, compared to the OBD group, without β -glucan supplementation. Of note is the predicted upstream regulation activation of MYC with β -glucan supplementation which was inhibited in OBD without β -glucan supplementation. The MYC proto-oncogene induces genes involved in glycolysis and stimulates lipid synthesis genes [54]. Overexpression of MYC can lower lipid accumulation in murine livers [55]. Additionally, MYC inhibition is associated with increased lipid accumulation due to mitochondrial dysfunction [56]. This could be a mechanism through which β -glucan may increase insulin sensitivity and decrease hepatic steatosis.

The differential effect of the obese type 2 diabetes microbiome on insulin resistance, hepatic lipid and metabolite profiles, with associated hepatic proteome profiles compared to an obese healthy microbiome, is novel. We show that obesity alone is not sufficient to impair metabolic health and indeed, within equivalent obese states the metabolic impact of diabetes on the microbiota can be substantial. Additionally, functional foods ingredients such as β -glucan supplementation can partly reverse the adverse OBD induced metabolic phenotype. We acknowledge that the faecal microbiota transplantation experiment is limited to one human donor per metabolic health type due to ethical, practical and financial limitations of pre-clinical models. Additionally, faecal energy measurement following β -glucan supplementation should be a focus in future studies. Also given the inherent link between metabolism and inflammation, more detailed work in relation to liver associated macrophage biology is warranted. Further studies are required to validate these findings and determine if / how therapeutic effect of β -glucan supplementation were coincidental or directly ascribed to microbiome modulation.

Acknowledgments

We would like to thank APC colleagues, Edel M. Cormac and Werner Frei for technical assistance in DNA isolation and sequencing of human faecal samples, and Cara M. Hueston, Céline Ribière and Marta Perez for assistance with the mouse experiment. We gratefully acknowledge the study participants for their interest and contributing their samples.

Funding

This work was principally funded by the Irish Department of Agriculture, Food and the Marine (14/F/828 “ImmunoMet” Programme) K.A.J.M., P.W.O’T. and H.M.R. K.A.J.M. was also funded by Precision Oncology Ireland (18/SPP/3522), a Science Foundation Ireland Strategic Partnership Programme. F.M.F. is supported by a Career Development Award from the Saolta University Healthcare Group. Work in H.M.R.’s laboratory is also funded by Science Foundation Ireland Frontiers Award Programme (SFI 19/FFP/6625).

Author Contributions

Conceptualization, H.M.R and P.W.O’T.; Methodology, E.M.O’C, H.M.R and P.W.O’T.; Formal Analysis, K.A.J.M., T.T.T.T, E.T.D, K.V. and S.M.H.; Investigation, K.A.J.M, K.V. and A. N.; Resources, E.M.O’C, H.M.R and P.W.O’T.; Data Curation, K.A.J.M., T.T.T.T, E.T.D and S.M.H.; Writing – Original Draft, K.A.J.M., T.T.T.T., H.M.R and P.W.O’T.; Writing – Review & Editing, all authors; Visualization, K.A.J.M., T.T.T.T; Supervision, E.M.O’C, H.M.R and P.W.O’T.; Funding Acquisition, E.M.O’C, H.M.R and P.W.O’T.

Declaration of Interests

The authors declare no competing interests, except that up until 2017, F.M. Finucane received honoraria, travel grants and have served on advisory boards for Novo Nordisk, Eli Lilly, Ethicon, Pfizer Inc., Sanofi-Aventis, Astra Zeneca, Merck-Serono, Boehringer Ingelheim, Janssen and Novartis.

Figure Title and Legends




Figure 1. Mice that received obese diabetic microbiome displayed altered metabolic phenotype and increased hepatic lipid accumulation. (A) Experimental design for murine intervention study. Conventional mice (N=8-9) were inoculated with human gut microbiota (HGM) from either an obese healthy (OBH) or an obese type 2 diabetes (OBD) subject at week 0 for three days. Arrows indicate the week on which the faecal samples were collected. AFG, antifungal gavage; GTT, glucose tolerance testing; ITT, insulin tolerance testing; LFD, low-fat diet; HFD, high-fat diet. (B) Response to glucose, insulin and glucose stimulated insulin secretion, (C) GTT incremental area under the curve (iAUC), (D) ITT area under the curve (AUC) and (E) HOMA-IR following HFD. Hepatic TAG (F) and cholesterol (G) were measured. Citrate and lactate levels within the liver are shown in (H) and (I) respectively. (J) Markers of hepatic lipid metabolism were assessed by RT-PCR with 18S as the appropriate housekeeping gene. Data are represented as $\pm$ SEM. * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$ with respect to (WRT) OBD vs OBH, # $p \leq 0.05$ WRT OBD vs OBD+BG, ††† $p \leq 0.001$ WRT OBH vs OBH+BG, ¥¥¥ $p \leq 0.001$ WRT OBH vs OBD+BG.





Figure 2. Dietary supplementation with β -glucan drives gut microbiota diversity changes in obese healthy and obese type 2 diabetes inoculated mice. (A) Difference in α -diversity between BG- and BG+ were determined by Mann–Whitney U test adjusted using Benjamini–Hochberg correction, **adjusted $p \leq 0.01$. **(B)** Principle coordinates analysis plots based on Bray–Curtis dissimilarity. The significant differences between groups were calculated by permutational multivariate analysis of variance (PERMANOVA) tests.





Accepted Article

Accepted Article

Accepted Article

Accepted Article

Accepted Article

Accepted Article

- Accepted Article

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9. *Diabetes Res Clin Pract* 2019, 157, 107843.

[2] Kaiser, A. B., Zhang, N., Pluijm, W., Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028). *Diabetes* 2018, 67:202-LB.doi: 10.2337/db18-202-LB.

[3] Centers for Disease Control and Prevention, National diabetes statistics report: estimates of diabetes and its burden in the United States. 2017, <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>.

[4] Umirah, F., Neoh, C. F., Ramasamy, K., Lim, S. M., Differential gut microbiota composition between type 2 diabetes mellitus patients and healthy controls: A systematic review. *Diabetes Res Clin Pract* 2021, 173, 108689.

[5] Tierney, A. C., McMonagle, J., Shaw, D. I., Gulseth, H. L., Helal, O., Saris, W. H. M., Paniagua, J. A., Gołębek-Leszczynska, I., Defoort, C., Williams, C. M., Karslström, B., Vessby, B., Dembinska-Kiec, A., López-Miranda, J., Blaak, E. E., Drevon, C. A., Gibney, M. J., Lovegrove, J. A., Roche, H. M., Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome—LIPGENE: a European randomized dietary intervention study. *International Journal of Obesity* 2010, 35, 800-809.

[6] Ralston, J. C., Lyons, C. L., Kennedy, E. B., Kirwan, A. M., Roche, H. M., Fatty Acids and NLRP3 Inflammasome-Mediated Inflammation in Metabolic Tissues. <https://doi.org/10.1146/annurev-nutr-071816-064836> 2017, 37, 77-102.

[7] Finucane, O. M., Lyons, C. L., Murphy, A. M., Reynolds, C. M., Klinger, R., Healy, N. P., Cooke, A. A., Coll, R. C., McAllan, L., Nilaweera, K. N., O'Reilly, M. E., Tierney, A. C., Morine, M. J., Alcala-Diaz, J. F., Lopez-Miranda, J., O'Connor, D. P., O'Neill, L. A., McGillicuddy, F. C., Roche, H. M., Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1 β secretion and insulin resistance despite obesity. *Diabetes* 2015, 64, 2116-2128.

[8] Vessby, B., Uusitupa, M., Hermansen, K., Riccardi, G., Rivellese, A. A., Tapsell, L. C., Nälsén, C., Berglund, L., Louheranta, A., Rasmussen, B. M., Calvert, G. D., Maffetone, A., Pedersen, E., Gustafsson, I. B., Storlien, L. H., Study, K., Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. *Diabetologia* 2001, 44, 312-319.

[9] Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., Risérus, U., Overfeeding Polyunsaturated and Saturated Fat Causes Distinct Effects on Liver and Visceral Fat Accumulation in Humans. *Diabetes* 2014, 63, 2356-2368.

[10] Yubero-Serrano, E. M., Delgado-Lista, J., Tierney, A. C., Perez-Martinez, P., Garcia-Rios, A., Alcala-Diaz, J. F., Castaño, J. P., Tinahones, F. J., Drevon, C. A., Defoort, C., Blaak, E. E., Dembinska-Kieć, A., Risérus, U., Lovegrove, J. A., Perez-Jimenez, F., Roche, H. M., Lopez-Miranda, J., Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: the LIPGENE study. *Am J Clin Nutr* 2015, 102, 1509-1517.

[11] Weickert, M. O., Department of Endocrinology and Diabetes, U. H. C. a. W. N. T., United Kingdom, Centre of Applied Biological & Exercise Sciences, C. U., Coventry, United Kingdom, Pfeiffer, A. F., German Institute of Human Nutrition, D. o. C. N., Department of Endocrinology, D. a. N., Charité-University-Medicine-Berlin, Berlin, Germany, Impact of Dietary Fiber Consumption on Insulin Resistance and the Prevention of Type 2 Diabetes. *The Journal of Nutrition* 2018, 148, 7-12.

[12] Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., Le Chatelier, E., Levenez, F., Dore, J., Mattila, I., Plichta, D. R., Poho, P., Hellgren, L. I., Arumugam, M., Sunagawa, S., Vieira-Silva, S., Jorgensen, T., Holm, J. B., Trost, K., Meta, H. I. T. C., Kristiansen, K., Brix, S., Raes, J., Wang, J., Hansen, T., Bork, P., Brunak, S., Oresic, M., Ehrlich, S. D., Pedersen, O., Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature* 2016, 535, 376-381.

- [13] Zmora, N., Suez, J., Elinav, E., You are what you eat: diet, health and the gut microbiota. *Nature Reviews Gastroenterology & Hepatology* 2018, 16, 35-56.
- [14] Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Pedersen, H. K., Arumugam, M., Kristiansen, K., Voigt, A. Y., Vestergaard, H., Hercog, R., Costea, P. I., Kultima, J. R., Li, J., Jorgensen, T., Levenez, F., Dore, J., Meta, H. I. T. c., Nielsen, H. B., Brunak, S., Raes, J., Hansen, T., Wang, J., Ehrlich, S. D., Bork, P., Pedersen, O., Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature* 2015, 528, 262-266.
- [15] Allin, K. H., Nielsen, T., Pedersen, O., Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus. *Eur J Endocrinol* 2015, 172, R167-177.
- [16] De Marco Castro, E., Calder, P. C., Roche, H. M., β -1,3/1,6-Glucans and Immunity: State of the Art and Future Directions. *Mol Nutr Food Res* 2020, e1901071.
- [17] Kusmiati, Dhewantara, F. X., Cholesterol-Lowering Effect of Beta Glucan Extracted from *Saccharomyces cerevisiae* in Rats. *Sci Pharm* 2016, 84, 153-165.
- [18] Silva Vde, O., Lobato, R. V., Andrade, E. F., de Macedo, C. G., Napimoga, J. T., Napimoga, M. H., Messori, M. R., Murata, R. M., Pereira, L. J., beta-Glucans (*Saccharomyces cerevisiae*) Reduce Glucose Levels and Attenuate Alveolar Bone Loss in Diabetic Rats with Periodontal Disease. *PLoS One* 2015, 10, e0134742.
- [19] Aoki, S., Iwai, A., Kawata, K., Muramatsu, D., Uchiyama, H., Okabe, M., Ikesue, M., Maeda, N., Uede, T., Oral administration of the *Aureobasidium pullulans* -derived β -glucan effectively prevents the development of high fat diet-induced fatty liver in mice. *Scientific Reports* 2015, 5, 1-10.
- [20] Cao, Y., Zou, S., Xu, H., Li, M., Tong, Z., Xu, M., Xu, X., Hypoglycemic activity of the Baker's yeast beta-glucan in obese/type 2 diabetic mice and the underlying mechanism. *Mol Nutr Food Res* 2016, 60, 2678-2690.
- [21] Velikonja, A., Lipoglavsek, L., Zorec, M., Orel, R., Avgustin, G., Alterations in gut microbiota composition and metabolic parameters after dietary intervention with barley beta glucans in patients with high risk for metabolic syndrome development. *Anaerobe* 2019, 55, 67-77.
- [22] Tran, T. T. T., Cousin, F. J., Lynch, D. B., Menon, R., Brulc, J., Brown, J. R. M., O'Herlihy, E., Butto, L. F., Power, K., Jeffery, I. B., O'Connor, E. M., O'Toole, P. W., Prebiotic supplementation in frail older people affects specific gut microbiota taxa but not global diversity. *Microbiome* 2019, 7, 39.
- [23] Heimesaat, M. M., Bereswill, S., Fischer, A., Fuchs, D., Struck, D., Niebergall, J., Jahn, H. K., Dunay, I. R., Moter, A., Gescher, D. M., Schumann, R. R., Gobel, U. B., Liesenfeld, O., Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with *Toxoplasma gondii*. *J Immunol* 2006, 177, 8785-8795.
- [24] Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., Glockner, F. O., Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. *Nucleic Acids Res* 2013, 41, e1.
- [25] Ralston, J. C., Mitchelson, K. A. J., Lynch, G. M., Tran, T. T. T., Wang, H., Strain, C. R., Lenighan, Y. M., Kennedy, E. B., Stanton, C., McGillicuddy, F. C., Su, Q., O'Toole, P. W., Roche, H. M., Microbiome Transfer Partly Overrides Lack of IL-1RI Signaling to Alter Hepatic but not Adipose Tissue Phenotype and Lipid Handling following a High-Fat Diet Challenge. *Mol Nutr Food Res* 2021, 65, e2000202.
- [26] McGillicuddy, F. C., Harford, K. A., Reynolds, C. M., Oliver, E., Claessens, M., Mills, K. H., Roche, H. M., Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. *Diabetes* 2011, 60, 1688-1698.
- [27] Lenighan, Y. M., Nugent, A. P., Moloney, A. P., Monahan, F. J., Walton, J., Flynn, A., Roche, H. M., McNulty, B. A., A modelling approach to investigate the impact of consumption of three different beef compositions on human dietary fat intakes. *Public Health Nutr* 2020, 23, 2373-2383.
- [28] Rappsilber, J., Mann, M., Ishihama, Y., Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. *Nat Protoc* 2007, 2, 1896-1906.

- [29] Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* 2008, 26, 1367-1372.
- [30] Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., Mann, M., Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome Res* 2011, 10, 1794-1805.
- [31] Cox, J., Hein, M. Y., Lubner, C. A., Paron, I., Nagaraj, N., Mann, M., Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics* 2014, 13, 2513-2526.
- [32] Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., Cox, J., The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat Methods* 2016, 13, 731-740.
- [33] Krämer, A., Green, J., Pollard, J., Tugendreich, S., Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics* 2014, 30, 523-530.
- [34] R Core Team, R Foundation for Statistical Computing, Vienna, Austria 2016.
- [35] Oksanen, J., Blanchet, F. G., Kindt, R., Legendre, P., Minchin, P. R., O'Hara, R. B., Simpson, G. L., Solymos, P., Stevens, M. H. H., Wagner, H., vegan: Community Ecology Package. *R package version 2.5-5*. <https://CRAN.R-project.org/package=vegan> 2019.
- [36] Bauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O'Brien, C. A., Lam, T. K. T., Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway. *Cell Metab* 2018, 27, 101-117 e105.
- [37] El Khoury, D., Cuda, C., Luhovyy, B. L., Anderson, G. H., Beta glucan: health benefits in obesity and metabolic syndrome. *J Nutr Metab* 2012, 2012, 851362.
- [38] Ho, H. V., Sievenpiper, J. L., Zurbau, A., Blanco Mejia, S., Jovanovski, E., Au-Yeung, F., Jenkins, A. L., Vuksan, V., The effect of oat β -glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. *Br J Nutr* 2016, 116, 1369-1382.
- [39] Nicolosi, R., Bell, S. J., Bistrian, B. R., Greenberg, I., Forse, R. A., Blackburn, G. L., Plasma lipid changes after supplementation with beta-glucan fiber from yeast. *Am J Clin Nutr* 1999, 70, 208-212.
- [40] Cao, Y., Sun, Y., Zou, S., Li, M., Xu, X., Orally Administered Baker's Yeast beta-Glucan Promotes Glucose and Lipid Homeostasis in the Livers of Obesity and Diabetes Model Mice. *J Agric Food Chem* 2017, 65, 9665-9674.
- [41] Yu, L., Li-Hawkins, J., Hammer, R. E., Berge, K. E., Horton, J. D., Cohen, J. C., Hobbs, H. H., Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. *J Clin Invest* 2002, 110, 671-680.
- [42] Dao, M. C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger, E. O., Kayser, B. D., Levenez, F., Chilloux, J., Hoyle, L., Consortium, M. I.-O., Dumas, M. E., Rizkalla, S. W., Dore, J., Cani, P. D., Clement, K., Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* 2016, 65, 426-436.
- [43] Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., Chen, Y., Ji, L., Human gut microbiota changes reveal the progression of glucose intolerance. *PLoS One* 2013, 8, e71108.
- [44] Ghosh, T. S., Das, M., Jeffery, I. B., O'Toole, P. W., Adjusting for age improves identification of gut microbiome alterations in multiple diseases. *Elife* 2020, 9.
- [45] Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., de Barse, M., Loumaye, A., Hermans, M. P., Thissen, J. P., de Vos, W. M., Cani, P. D., Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. *Nat Med* 2019, 25, 1096-1103.
- [46] Woting, A., Pfeiffer, N., Loh, G., Klaus, S., Blaut, M., Clostridium ramosum promotes high-fat diet-induced obesity in gnotobiotic mouse models. *MBio* 2014, 5, e01530-01514.

- [47] Vital, M., Howe, A. C., Tiedje, J. M., Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. *mBio* 2014, 5, e00889.
- [48] Rey, F. E., Faith, J. J., Bain, J., Muehlbauer, M. J., Stevens, R. D., Newgard, C. B., Gordon, J. I., Dissecting the in vivo metabolic potential of two human gut acetogens. *J Biol Chem* 2010, 285, 22082-22090.
- [49] Krisko, T. I., Nicholls, H. T., Bare, C. J., Holman, C. D., Putzel, G. G., Jansen, R. S., Sun, N., Rhee, K. Y., Banks, A. S., Cohen, D. E., Dissociation of Adaptive Thermogenesis from Glucose Homeostasis in Microbiome-Deficient Mice. *Cell Metab* 2020, 31, 592-604 e599.
- [50] Kajani, S., Curley, S., O'Reilly, M. E., Yin, X., Dillon, E. T., Guo, W., Nilaweera, K. N., Brennan, L., Roche, H. M., McGillicuddy, F. C., Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1 β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport. *Mol Metab* 2022, 56, 101425.
- [51] Sun, W., Nie, T., Li, K., Wu, W., Long, Q., Feng, T., Mao, L., Gao, Y., Liu, Q., Gao, X., Ye, D., Yan, K., Gu, P., Xu, Y., Zhao, X., Chen, K., Loomes, K. M., Lin, S., Wu, D., Hui, X., Erratum. Hepatic CPT1A Facilitates Liver-Adipose Cross Talk via Induction of FGF21 in Mice. *Diabetes* 2022;71:31-42. *Diabetes* 2022.
- [52] White, P. J., Lapworth, A. L., An, J., Wang, L., McGarrah, R. W., Stevens, R. D., Ilkayeva, O., George, T., Muehlbauer, M. J., Bain, J. R., Trimmer, J. K., Brosnan, M. J., Rolph, T. P., Newgard, C. B., Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. *Mol Metab* 2016, 5, 538-551.
- [53] Newgard, C. B., Metabolomics and Metabolic Diseases: Where Do We Stand? *Cell Metab* 2017, 25, 43-56.
- [54] Dang, C. V., MYC, metabolism, cell growth, and tumorigenesis. *Cold Spring Harb Perspect Med* 2013, 3.
- [55] Xin, B., Yamamoto, M., Fujii, K., Ooshio, T., Chen, X., Okada, Y., Watanabe, K., Miyokawa, N., Furukawa, H., Nishikawa, Y., Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways. *Oncogene* 2017, 36, 5087-5097.
- [56] Zirath, H., Frenzel, A., Oliynyk, G., Segerström, L., Westermark, U. K., Larsson, K., Munksgaard Persson, M., Hultenby, K., Lehtiö, J., Einvik, C., Pålman, S., Kogner, P., Jakobsson, P. J., Henriksson, M. A., MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. *Proc Natl Acad Sci U S A* 2013, 110, 10258-10263.

Gut microbiota dysbiosis is associated with obesity and type 2 diabetes. This study demonstrates obese diabetic microbiome transplantation specifically induced hepatic steatosis and insulin resistance following high-fat diet, which was resolved by yeast β -glucan supplementation, reverting adverse metabolic impacts in murine recipients of obese diabetic microbiome. Understanding the interaction between diet, gut microbiota and host metabolism might improve the efficacy of dietary management of metabolic disorders

